VE11 Stock Overview
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aravive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.039 |
| 52 Week High | US$1.87 |
| 52 Week Low | US$0.035 |
| Beta | 2.19 |
| 1 Month Change | -64.86% |
| 3 Month Change | -69.29% |
| 1 Year Change | n/a |
| 3 Year Change | -99.07% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| VE11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.5% | 2.1% | -1.0% |
| 1Y | n/a | -22.2% | 2.0% |
Return vs Industry: Insufficient data to determine how VE11 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how VE11 performed against the German Market.
Price Volatility
| VE11 volatility | |
|---|---|
| VE11 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VE11's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VE11's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | n/a | aravive.com |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
Aravive, Inc. Fundamentals Summary
| VE11 fundamental statistics | |
|---|---|
| Market cap | €2.73m |
| Earnings (TTM) | -€36.83m |
| Revenue (TTM) | €6.46m |
0.4x
P/S Ratio-0.1x
P/E RatioIs VE11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VE11 income statement (TTM) | |
|---|---|
| Revenue | US$6.99m |
| Cost of Revenue | US$53.39m |
| Gross Profit | -US$46.39m |
| Other Expenses | -US$6.55m |
| Earnings | -US$39.85m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -663.34% |
| Net Profit Margin | -569.73% |
| Debt/Equity Ratio | 0% |
How did VE11 perform over the long term?
See historical performance and comparison